These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model. Zhu J; Yu M; Chen L; Kong P; Li L; Ma G; Ge H; Cui Y; Li Z; Pan H; Xie H; Zhou W; Wang S Diagn Interv Imaging; 2018 Mar; 99(3):135-142. PubMed ID: 29398572 [TBL] [Abstract][Full Text] [Related]
23. Combinatorial immunotherapy induces tumor-infiltrating CD8 Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555 [TBL] [Abstract][Full Text] [Related]
24. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Redmond WL; Linch SN; Kasiewicz MJ Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278 [TBL] [Abstract][Full Text] [Related]
25. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344 [TBL] [Abstract][Full Text] [Related]
26. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Linch SN; McNamara MJ; Redmond WL Front Oncol; 2015; 5():34. PubMed ID: 25763356 [TBL] [Abstract][Full Text] [Related]
27. Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer. Momenzadeh N; Hajian S; Shabankare A; Ghavimi R; Kabiri-Samani S; Kabiri H; Hesami-Zadeh K; Shabankareh ANT; Nazaraghay R; Nabipour I; Mohammadi M Int Immunopharmacol; 2023 Feb; 115():109622. PubMed ID: 36577156 [TBL] [Abstract][Full Text] [Related]
28. Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy. Sun Z; Chu Y; Xiao J; Yang Y; Meng F; Wang X; Dong Y; Zhu J; Wu Y; Qin L; Ke Y; Liu B; Liu Q J Transl Med; 2023 Sep; 21(1):619. PubMed ID: 37700338 [TBL] [Abstract][Full Text] [Related]
29. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis. Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055 [TBL] [Abstract][Full Text] [Related]
30. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4 Saleh R; Toor SM; Khalaf S; Elkord E Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877 [No Abstract] [Full Text] [Related]
31. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models. Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of PD-1 blockade in cervical cancer is related to a CD8 Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279 [TBL] [Abstract][Full Text] [Related]
33. Foxp3 Kohno M; Murakami J; Wu L; Chan ML; Yun Z; Cho BCJ; de Perrot M J Immunol; 2020 Nov; 205(9):2519-2531. PubMed ID: 32948683 [TBL] [Abstract][Full Text] [Related]
34. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205 [No Abstract] [Full Text] [Related]
35. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840 [TBL] [Abstract][Full Text] [Related]
36. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190 [TBL] [Abstract][Full Text] [Related]
37. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Terranova-Barberio M; Thomas S; Ali N; Pawlowska N; Park J; Krings G; Rosenblum MD; Budillon A; Munster PN Oncotarget; 2017 Dec; 8(69):114156-114172. PubMed ID: 29371976 [TBL] [Abstract][Full Text] [Related]
38. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976 [TBL] [Abstract][Full Text] [Related]
40. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]